Merck Sharp Takes Aim At Halozyme's UK Drug Delivery IP
Merck Sharp & Dohme has asked a London court to revoke an under-the-skin drug delivery patent belonging to Halozyme, arguing that the blueprint isn't inventive because it solves no technical problem....To view the full article, register now.
Already a subscriber? Click here to view full article